Drug Profile
Relacatib - GlaxoSmithKline
Alternative Names: 462795; GSK-462795; SB-462795Latest Information Update: 31 Jul 2020
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Human Genome Sciences
- Class Azepines; Osteoporosis therapies; Sulfones
- Mechanism of Action Cathepsin K inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer metastases; Osteoarthritis; Postmenopausal osteoporosis
Most Recent Events
- 10 Jan 2006 Phase-II clinical trials in Cancer metastases in USA (PO)
- 15 Dec 2005 Phase-I clinical trials in Cancer metastases in USA (unspecified route)
- 16 Dec 2003 This compound is still in active development